Rosetta Genomics To Host Second Quarter 2010 Conference Call On Wednesday, September 8, 2010
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider
of microRNA-based molecular diagnostic tests, today announced that the
Company will release financial results for the three and six months
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June 30, 2010, after the market closes on Tuesday, September 7, 2010. Kenneth A. Berlin, President and Chief Executive Officer, and Limor Zur – Stoller, Vice President-Finance, will host a conference call for investors beginning at 10:00 a.m. Eastern time on Wednesday, September 8, 2010 to discuss the second quarter 2010 financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 866-239-5859 (domestic) or 702-495-1913 (international) and entering passcode 89504316 a few minutes before 10:00 a.m. Eastern time on Wednesday, September 8, 2010. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.rosettagenomics.com. A replay of the conference call will be accessible two hours after its completion through September 10, 2010 by dialing 800-642-1687 (domestic) or 706-645-9291 (international) and entering passcode 89504316. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.rosettagenomics.com. About Rosetta Genomics Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit www.rosettagenomics.com. Forward-Looking Statements Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the development of early detection cancer screening products, including a non-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2009 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.